The real-world study compared the efficacy of neoadjuvant chemotherapy plus immunotherapy vs chemotherapy alone in patients with cT2-4bN0-3M0-1a pathological and imaging diagnosed MIBC.
Since patients with poor PS (≥2) were excluded from trials analyzing this new standard of care for mRCC treatment, the study aimed to assess the efficacy and safety of immune checkpoint combination therapy in this group of patients.
The network meta-analysis aimed to compare various combinations of treatment options to determine the safest and most effective management strategy for mCSPC.
The study included a total of 183 patients with genitourinary cancers.
Patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy were included in the analysis.
The case-based study aimed to analyze the prescribing behaviors of community oncologists treating patients with aRCC.
Suppressed drug metabolism was identified in patients with various inflammatory conditions.
The meta-analysis included 69 RCTs with a total of 27,079 patients.
Despite an increasing emphasis on HFmrEF over the past several years, there is a lack of authoritative guidance surrounding therapeutic approaches for these patients.
Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the treatment of hypertension according to US and European guidelines.
